Protagenic Therapeutics announced that the company’s Board of Directors has approved a 1-for-4 reverse stock split of the company’s issued and outstanding common stock. The company elaborated that following shareholder approval at the Annual Meeting of the stockholders held on November 23, 2022 granting the Board the authority to effect a reverse split if necessary to comply with Nasdaq Rule 5550(a)(2) regarding minimum bid price, the company’s Board of Directors has approved a 1-for-4 reverse stock split of the company’s issued and outstanding shares of common stock, par value $0.0001 per share effective upon the related Amendment to the company’s Third Amended and Restated Certificate of Incorporation becoming effective pursuant to Delaware law. Beginning with the opening of trading on or about March 23, 2023, the company’s Common Stock will trade on the Nasdaq on a split-adjusted basis under the new CUSIP number 74365N202 and will continue to trade under the symbol "PTIX."
Published first on TheFly